Detailed Information

Cited 17 time in webofscience Cited 24 time in scopus
Metadata Downloads

Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents

Authors
Li, Yong-JianRha, Seung-WoonChen, Kang-YinPoddar, Kanhaiya L.Jin, ZheMinami, YoshiyasuWang, LinDang, QunLi, Guang-PingRamasamy, SureshkumarPark, Ji-YoungChoi, Chol UngKim, Jin-WonKim, Eung JuPark, Chang GyuSeo, Hong SeogOh, Dong JooJeong, Myung HoAhn, Young KeunHong, Taek JongPark, Jong-SeonKim, Young JoHur, Seung HoSeong, In WhanChae, Jei KeonCho, Myeong ChanBae, Jang HoChoi, Dong HoonJang, Yang SooChae, In HoKim, Hyo SooKim, Chong JinYoon, Jung HanAhn, Tae HoonTahk, Seung-JeaChung, Wook SungSeung, Ki BaePark, Seung Jung
Issue Date
Apr-2010
Publisher
MOSBY-ELSEVIER
Citation
AMERICAN HEART JOURNAL, v.159, no.4, pp 684 - U218
Indexed
SCI
SCIE
SCOPUS
Journal Title
AMERICAN HEART JOURNAL
Volume
159
Number
4
Start Page
684
End Page
U218
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/15059
DOI
10.1016/j.ahj.2009.12.041
ISSN
0002-8703
1097-6744
Abstract
Background Whether low-molecular-weight heparin (LMWH) is superior to unfractionated heparin (UFH) in acute ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) remains unclear. Methods A total of 3,372 STEMI patients who underwent primary PCI with DESs received either LMWH (n = 1,531 patients, subcutaneous enoxaparin 1 mg/kg, bid for 3-5 days plus reduced dose of UFH [ 50 U/kg] during PCI) or UFH alone (n = 1,841 patients, intravenous bolus injection of 5,000 U, followed by 24,000 U/d infusion for at least 48 hours). The bleeding events and clinical outcomes during in-hospital and at 8 months were compared. Results The incidences of major and minor bleeding events were similar between the 2 groups. Multivariable Cox regression analysis showed that LMWH group had lower incidences of cardiac death (adjusted odds ratio [OR] 0.55, 95% CI 0.39-0.77, P<.001), total death (adjusted OR 0.50, 95% CI 0.37-0.68, P<.001), and total major adverse cardiac events (adjusted OR 0.77, 95% CI 0.62-0.95, P=.017) at 8 months as compared with UFH group. Similar results were obtained across different subgroups including different DESs, age, and sex. Conclusions The LMWH enoxaparin combined with reduced dose of UFH (50 U/kg) administration as an adjunctive antithrombotic therapy in STEMI patients undergoing primary PCI with DESs seems to be safe and efficacious. However, randomized clinical trials are needed to confirm this conclusion. (Am Heart J 2010; 159: 684-690. e1.)
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Cardiology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Seo, Hong Seog photo

Seo, Hong Seog
Guro Hospital (Department of Cardiology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE